Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment, Renal cell carcinoma treatment, and Prostate Cancer Treatment and Research.
Racial and Ethnic Disparities in the Utilization of Partial Nephrectomy and Robotic Surgery for Renal Cell Carcinoma
Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial
Single bladder instillation of gemcitabine versus mitomycin C after minimally invasive radical nephroureterectomy: A propensity-score match analysis from the ROBUUST 2.0 collaborative group
A pretreatment nomogram to predict muscle-invasiveness in high-risk upper tract urothelial carcinoma (ROBUUST 2.0 collaborative group)
Radical nephroureterectomy vs kidney sparing surgery for upper tract urothelial carcinoma in solitary kidney patients: a multi-institutional analysis of the ROBUUST 2.0 registry
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer
Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group
GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma
Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer
Survival Outcomes by Race Following Surgical Treatment for Upper Tract Urothelial Carcinoma
Robotic distal ureterectomy for high-risk distal ureteral urothelial carcinoma: a retrospective multicenter comparative analysis (ROBUUST 2.0 collaborative group)
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry
The impact of post‐nephroureterectomy surgically induced chronic kidney disease on survival outcomes
Evaluating 4Kscore’s role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score
Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study
Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression
Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
Robotic <i>vs</i> Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair “tetrafecta” Analysis (ROBUUST Collaborative Group)
Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry
Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence
Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance
Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration)
Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy